#Biotech M&A

Total 1 articles

An abstract biotech image symbolizing the collaboration between Novartis and SciNeuro for treating neurological diseases.

Novartis SciNeuro Alzheimer Deal 2026: A $1.7 Billion Bet on Brain Health

Novartis enters a $1.7 billion Novartis SciNeuro Alzheimer deal 2026 to develop next-gen anti-amyloid treatments using blood-brain barrier shuttle technology.

Jan 13, 2026